

1 Thomas E. Drendel, Esq.
Nevada State Bar No. 0655
2 BRADLEY, DRENDEL & JEANNEY, LTD.
P.O. Box 1987
3 Reno, Nevada 89505
Telephone No. (775) 335-9999
4 Facsimile No. (775) 335-9993

5 *Attorneys for Plaintiff*

6 UNITED STATES DISTRICT COURT

7 DISTRICT OF NEVADA

8 HOWARD MCMASTER,

Case No.

9 Plaintiff,

10 v.

11 FRANCK'S LAB, INC., doing business as
FRANCK'S COMPOUNDING LAB; PAUL
12 W. FRANCK; ANTHONY JAMES
CAMPBELL; and DOES 1 through 10,
13 inclusive,

14 Defendant.

15 **COMPLAINT AND JURY DEMAND**

16 COMES NOW, Plaintiff HOWARD MCMASTER, by and through his counsel of record,
17 Thomas E. Drendel, Esq., of the law offices of Bradley, Drendel & Jeanney, Ltd., and for causes
18 of action against the Defendants, and each of them, alleges:

19 **JURISDICTION & PARTIES**

20 1. This is an action for personal injuries arising from a defective product. This Court
21 has diversity jurisdiction as this is a controversy between parties of diverse citizenship and an
22 amount in controversy that exceeds \$75,000 pursuant to the provisions of 42 U.S.C. §1332.

23 2. Plaintiff, HOWARD MCMASTER, is a citizen of Reno, Nevada.

24 3. Defendant, FRANCK'S LAB, INC., dba FRANCK'S COMPOUNDING LAB is
25 a corporation incorporated under the laws of Florida with its principal place of business in the
26 State of Florida and selling compounded or formulated products for utilization in the medical
27 field, including Brilliant Blue-G ("BBG") dye; Triamcinolone ("TMC") and Avastin.
28

1 4. Defendant, PAUL W. FRANCK is a citizen of the State of Florida, is
2 a principal and shareholder of defendant FRANCK'S LAB INC. and was involved in the
3 management and operations of FRANCK'S LAB, INC., and direction the manner in which BBG,
4 TMC and Avastin were compounded in the laboratory.

5 5. Defendant, ANTHONY JAMES CAMPBELL, is a citizen of the State of Florida,
6 was a lead chemist with FRANCK'S LAB, INC. and had responsibility for overseeing the
7 laboratory operations and assuring compliance with the rules, laws and regulations concerning
8 compounding pharmacies, including the federal rules and regulations concerning the
9 manufacture, sale and distribution of drugs, including BBC, TMC and Avastin.

10 6. The true names and capacities of DOES 1 through 10 are unknown to Plaintiff at
11 this time. Plaintiff is informed and believes and thereon alleges that these DOE defendants are in
12 someway liable for the events referred to in this Complaint and caused damage to Plaintiff.
13 Plaintiff will amend this Complaint when their identities and relationship to his injuries are
14 discovered. Does 1 through 10 and not citizens of the State of Nevada or corporations with their
15 principal place of business in the State of Nevada.

16 7. Plaintiff is informed and believes that at all time herein mentioned, the
17 defendants, and each of them, were the agents, servants, employees, joint venturers, and partners
18 of each other and at all times were acting within the course and scope of said relationships.

19 8. Venue is proper in this district and in this, the unofficial northern division thereof,
20 because Plaintiff is a citizen in this district, the tort occurred in this district and the Defendants
21 were doing business in this district at the time of the injury.

22 **FIRST CAUSE OF ACTION**
23 **(FOR PRODUCT LIABILITY - NEGLIGENCE)**

24 9. Plaintiff incorporates herein by reference paragraphs 1-8 as though fully set forth
25 herein.

26 10. On November 15, 2011, Plaintiff underwent a vitrectomy procedure on his left
27 eye performed by Dr. Steven Friedlander at the Northern Nevada Medical Center located at 2375
28 E. Prater Way in Sparks, Nevada. During the procedure, Dr. Friedlander injected Plaintiff's eye

1 with BBG, the product the defendants formulated, manufactured, compounded, marketed and
2 sold as an appropriate product to be utilized in such procedure. The Defendants represented that
3 BBG was pure, sterile, and fit for the represented purpose of assisting in procedures like
4 vitrectomies and the product could be injected into an eyeball in order to assist the doctor in
5 achieving the desired result.

6 11. Plaintiff's condition worsened after the November 15, 2011, procedure, and he
7 lost his vision and use of his left eye.

8 12. Plaintiff was advised that numerous other patients who were injected with BBG
9 had suffered similar complications. Plaintiff was further advised that the sudden, unexpected and
10 unusual number of patients who developed the same or similar complications led to an
11 investigation by the doctor, the Federal Drug Enforcement Agency (FDA) and others which
12 concluded that all of the patients who suffered these complications due to BBG which was
13 negligently manufactured.

14 13. The investigation by numerous state, county and federal health agencies
15 concluded that the Defendants' BBG product was negligently manufactured and that the
16 Defendants had violated numerous federal rules and regulations. On July 9, 2012, the United
17 States Food and Drug Administration ("FDA") issued a Warning Letter FLA-12-38, which
18 advised PAUL W. FRANCK and FRANCK'S LAB, INC., that:

19 a. The subject BBG was adulterated within the meaning of Section 501(a)(1)
20 of the Act [21 U.S.C. § 351 (a)(1)] and that it was contaminated with filthy, putrid or
21 decomposed substances;

22 b. The BBG was adulterated within the meaning of Section 501(c) of the Act
23 [21 U.S.C. § 351 (c)] in that its strength different from, or its purity or quality fell below, that
24 which is purported to possess;

25 c. The BBG and all sterile drugs compounded by the defendants were
26 adulterated under Section 501(a)(2)(A) of the Act [21 U.S.C. § 351 (a)(2)(A)] in that they were
27 prepared, packed and stored under unsanitary conditions whereby they may have been
28 contaminated by filth;

1 d. The BBG was misbranded within the meaning of Section 502(a) of the Act
2 [21 U.S.C. § 352 (a)] because their labeling was false and misleading;

3 e. The FDA investigators observed numerous instances of unsanitary and
4 inappropriate practices by compounding technicians who left and re-entered clean rooms without
5 changing lab coats, who were touching non-sterile items while wearing their sterile gloves and
6 then returned to compounding activities, etc.; and

7 f. The BBG drug products were misbranded insofar as they were labeled as
8 being sterile, and they contained filthy, putrid, or decomposed substances.

9 14. The Defendants knew that failing to follow safe and appropriate compounding
10 practices could result in complications, including fatal ones. In 2009, the Defendants
11 compounded cocktails that were given to prized polo horses from the Venezuelan-owned
12 Lechuza Caracas team in preparation for championship matches near West Palm Beach, Florida.
13 Twenty-one of these prized polo horses died from errors committed by the Defendants in
14 compounding these cocktails.

15 15. The FDA investigation following the incident with the polo horses led the agency
16 to conclude that the defendants were mixing brews outside of federal guidelines and were
17 utilizing drugs that had not been approved for use in the United States.

18 16. Tragic complications of the patients who ended up receiving injections of the
19 contaminated BBG are just one example of the problems in the largely unregulated area of
20 compounding pharmacies. Recently, hundreds of patients who underwent steroid injections were
21 stricken with meningitis due to the contamination of the steroid fluid.

22 17. The Defendants owed a duty of reasonable care to Plaintiff to design, compound,
23 manufacture, market, sell and distribute the BBG in a condition that was safe for its intended
24 purpose and consistent with the representations that it was a sterile product. The Defendants'
25 duty included a duty to insure that the product did not cause patients who were injected with
26 BBG in their eye to suffer from unreasonable risks of injury from the product, especially in light
27 of the fact that it is known that infections in the eye are extremely difficult to treat.

28

1 18. Defendants breached their duty to Plaintiff in the testing, design, compounding,
2 manufacturing, packaging, storing, warnings, marketing, advertising, promotion and distribution
3 of BBG and otherwise failed to exercise ordinary care to avoid the risk of infection and harm.

4 19. The Defendants knew prior to the date of Plaintiff's surgery of November 15,
5 2011, that their dye was contaminated, non-sterile and unfit to be used in eye surgery
6 procedures; posed an unreasonably dangerous risk of infection and they failed to do anything to
7 recall the product from the market or warn the medical community and the public of the
8 substantial risk of serious complications.

9 20. The Defendants recklessly and wantonly conducted their laboratory compounding
10 practices in clear violation of applicable federal law and allowed such filthy and inappropriate
11 conditions to exist to the point that it was all but certain that the drugs they were compounding
12 were going to be contaminated.

13 21. The Defendants knew that the patients who were going to be injected with their
14 BBG were at risk for developing serious injuries and complications but they nevertheless
15 continued with their practices in conscious disregard of the health and safety of the ultimate
16 consumers of BBG.

17 22. As a direct, proximate and legal result of the negligence, carelessness,
18 recklessness and other wrongdoing actions of the Defendants, and each of them as described
19 herein, Plaintiff HOWARD MCMASTER sustained general damages from debilitating and
20 painful injuries including blindness of his left eye and was required to undergo additional
21 invasive surgeries and procedures, all to no avail, causing him additional pain, suffering, anxiety,
22 worry and depression. Plaintiff has also incurred and is likely to incur in the future, special
23 damages for medical, hospital and related services in an amount to be established at the time of
24 trial.

25 23. The Defendant's conduct was so reckless, malicious, oppressive, fraudulent and
26 despicable and carried on with a willful and conscious disregard for the safety of the patients who
27 were likely to be injected with BBG. Therefore, punitive damages should be imposed upon the
28 defendants, and each of them, by way of an example and to punish such conduct in an amount to
be determined by the trier of fact.

SECOND CAUSE OF ACTION
(FOR STRICT LIABILITY)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

24. Plaintiff incorporates herein by reference paragraphs 1-23 as though fully set forth herein.

25. The subject BBG was defective in its compounding and manufacture since it was different from the manufacturer's intended result as set forth on the packaging and related material that accompanied the product, specifically that the product was sterile and free of any contamination. Plaintiff is informed and believes that the batch of the product that included the BBG that was injected into his eye was defective in compounding and manufacture in that it differed from other batches of BBG from these defendants.

26. The defect in the compounding and manufacture of the product, specifically the contamination and non-sterile nature of the product, existed in the product when it left the possession of the defendants.

27. The defect in the compounding and manufacture of the BBG resulted in complications to the Plaintiff's procedure and blindness in his left eye.

28. The use of this contaminated BBG, by the Plaintiff or by his physician during his procedure, was completely foreseeable by the Defendants and each of them since the Plaintiff's doctor was utilizing the product as intended by the Defendants and the medical community.

29. The BBG injected into the Plaintiff's eye failed to perform as safely and reasonably as a consumer would expect when used as intended.

30. As a direct, proximate and legal result of the strict liability and other wrongdoing actions of the Defendants, and each of them as described herein, Plaintiff HOWARD MCMASTER suffered general damages from debilitating and painful injuries including blindness of his left eye and was required to undergo additional invasive surgeries and procedures, all to no avail, causing him additional pain, suffering, anxiety, worry and depression. Plaintiff has also incurred and is likely to incur in the future, special damages for medical, hospital and related services in an amount to be established at the time of trial.

///

1 31. The Defendant's conduct was so reckless, malicious, oppressive, fraudulent and
2 despicable and carried on with a willful and conscious disregard for the safety of the patients who
3 were likely to be injected with BBG. Therefore, punitive damages should be imposed upon the
4 defendants, and each of them, by way of an example and to punish such conduct in an amount to
5 be determined by the trier of fact.

6 **THIRD CAUSE OF ACTION**
7 **(FOR STRICT LIABILITY - FAILURE TO WARN)**

8 32. Plaintiff incorporates herein by reference paragraphs 1-31 as though fully set forth
9 herein.

10 33. The BBG which was injected into Plaintiff's eye on November 15, 2011, was
11 defective in that there was no warning on the product that it was, or could be, contaminated with
12 filth or foreign matter.

13 34. The Defendants, and each of them, knew that doctors would utilize their BBG
14 relying on the representations of the Defendants that the product was sterile and that they would
15 have no reason to believe that the product was not sterile and, in fact the Defendants knew, or
16 reasonably should have known based upon their background and experience, that a contaminated
17 dye to be injected into the eye could cause serious and debilitating injuries, including blindness
18 of the injected eye.

19 35. As a direct, proximate and legal result of the failure to warn and other wrongdoing
20 actions of the defendants, and each of them as described herein, Plaintiff HOWARD
21 MCMASTER suffered general damages from debilitating and painful injuries including
22 blindness of his left eye and was required to undergo additional invasive surgeries and
23 procedures, all to no avail, causing him additional pain, suffering, anxiety, worry and depression.
24 Plaintiff has also incurred and is likely to incur in the future, special damages for medical,
25 hospital and related services in an amount to be established at the time of trial.

26 36. Plaintiff understands that the defendants were aware of the problems with their
27 BBG prior to November 15, 2011, yet failed to recall the product, issue warnings to the medical
28 community or otherwise do anything to avert this contaminated product being injected into the
eye of patients like the Plaintiff.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

6. For cost of suit incurred herein; and

7. For any such other relief as the Court may deem appropriate.

DATED this 4 day of March 2013.

BRADLEY, DRENDEL & JEANNEY



Thomas Drendel, Esq.
Attorneys for Plaintiff

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA**

HOWARD MCMASTER, Case No. 3:13-cv-00100

Plaintiff,

v.

FRANCK'S LAB, INC., doing business as
FRANCK'S COMPOUNDING LAB; PAUL
W. FRANCK; ANTHONY JAMES
CAMPBELL; and DOES 1 through 10,
inclusive,

Defendants.

_____ /

SUMMONS

TO THE DEFENDANT: YOU HAVE BEEN SUED. THE COURT MAY DECIDE AGAINST YOU WITHOUT BEING HEARD UNLESS YOU RESPOND WITHIN 20 DAYS. READ THE INFORMATION BELOW VERY CAREFULLY.

A civil complaint has been filed by the plaintiff against you for the relief as set forth in that document (see complaint). When service is by publication, add a brief statement of the object of the action. See Rules of Civil Procedure, Rule 4 (b).

- 1. If you intend to defend this lawsuit, you must do the following within 20 days after service of this summons, exclusive of the day of service:
 - a. File with the Clerk of Court, whose address is shown below, a formal written answer to the complaint, along with the appropriate filing fees, in accordance with the rules of the Court; and
 - b. Serve a copy of your answer upon the attorney or plaintiff whose name and address is shown below.
- 2. Unless you respond, a default will be entered upon application of the plaintiff and this Court may enter a judgment against you for the relief demanded in the complaint.

Dated this _____ day of _____, 20__.

Issued on behalf of plaintiff's attorney

CLERK OF THE COURT

Name: Thomas Drendel, Esq.
Address: P.O. Box 1987
Reno, NV 89505
Phone Number: (775) 335-9999

Deputy Clerk

United States District Court
Bruce R. Thompson US Courthouse
400 South Virginia Street
Reno, NV 89501

AFFIDAVIT OF SERVICE

(For General Use)

STATE OF _____)
COUNTY OF _____)

_____, being first duly sworn, deposes and says: That affiant is a citizen of the United States, over 18 years of age, and that affiant received the Summons on the _____ day of _____, 20____, and personally served _____ the within named defendant, on the _____ day of _____, 20____, in _____, County of _____, State of _____, by delivering a copy of the Summons attached to a copy of the Complaint.

Signature of Person Making Service

Subscribed and sworn to before me this _____ day of _____, 20____.

Notary Public

AFFIDAVIT OF MAILING

(For use when service is by publication and mailing)

STATE OF NEVADA _____)
COUNTY OF WASHOE _____)

_____, being first duly sworn, deposes and says: That on the _____ day of _____, 20____, affiant deposited in the United States mail at Reno, Nevada, a copy of the Summons and Complaint addressed to _____

Signature of Person Making Service

Subscribed and sworn to before me this _____ day of _____, 20____.

Notary Public

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON THE REVERSE OF THE FORM.)

I. (a) PLAINTIFFS
HOWARD MCMASTER
(b) County of Residence of First Listed Plaintiff Washoe
(c) Attorney's (Firm Name, Address, and Telephone Number)
Thomas E. Drendel, Esq., Bradley, Drendel & Jeanney, Ltd., P.O.
Box 1987, Reno, Nevada, (775) 335-9999

DEFENDANTS
FRANCK'S LAB, INC., doing business as FRANCK'S
COMPOUNDING LAB; PAUL W. FRANCK; ANTHONY
County of Residence of First Listed Defendant
NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE
LAND INVOLVED.
Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)
1 U.S. Government Plaintiff
2 U.S. Government Defendant
3 Federal Question (U.S. Government Not a Party)
4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)
Citizen of This State
Citizen of Another State
Citizen or Subject of a Foreign Country
PTF DEF
1 1
2 2
3 3
Incorporated or Principal Place of Business In This State
Incorporated and Principal Place of Business In Another State
Foreign Nation
PTF DEF
4 4
5 5
6 6

IV. NATURE OF SUIT (Place an "X" in One Box Only)
Table with columns: CONTRACT, REAL PROPERTY, PERSONAL INJURY, CIVIL RIGHTS, PRISONER PETITIONS, FORFEITURE/PENALTY, LABOR, IMMIGRATION, BANKRUPTCY, SOCIAL SECURITY, FEDERAL TAX SUITS, OTHER STATUTES.

V. ORIGIN (Place an "X" in One Box Only)
1 Original Proceeding
2 Removed from State Court
3 Remanded from Appellate Court
4 Reinstated or Reopened
5 Transferred from another district (specify)
6 Multidistrict Litigation
7 Appeal to District Judge from Magistrate Judgment

VI. CAUSE OF ACTION
Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):
42 USC § 1332
Brief description of cause: Product Liability

VII. REQUESTED IN COMPLAINT:
CHECK IF THIS IS A CLASS ACTION UNDER F.R.C.P. 23
DEMAND \$ EXCESS OF \$75,000
CHECK YES only if demanded in complaint:
JURY DEMAND: Yes No

VIII. RELATED CASE(S) IF ANY
(See instructions): JUDGE DOCKET NUMBER

DATE 3/4/2013
SIGNATURE OF ATTORNEY OF RECORD [Signature]

FOR OFFICE USE ONLY
RECEIPT # AMOUNT APPLYING IFP JUDGE MAG. JUDGE